<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03425006</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC# 09517; IRB# 828910</org_study_id>
    <nct_id>NCT03425006</nct_id>
  </id_info>
  <brief_title>Pembrolizumab and Itacitinib (INCB039110) for NSCLC</brief_title>
  <official_title>Phase II Study of Pembrolizumab and Itacitinib (INCB039110) for First Line Treatment of Metastatic Non-Small Cell Lung Cancer Expressing PD-L1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, single arm phase 2 study to establish the safety and efficacy of&#xD;
      itacitinib (also known as INCB039110) administered in combination with pembrolizumab in&#xD;
      patients with metastatic PD-L1 positive non-small cell lung cancer (NSCLC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Administrative reasons&#xD;
  </why_stopped>
  <start_date type="Actual">June 18, 2018</start_date>
  <completion_date type="Actual">October 11, 2021</completion_date>
  <primary_completion_date type="Actual">June 17, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate at 12 weeks according to RECIST 1.1 for the combination of pembrolizumab and itacitinib among patients with previously untreated, PD-L1 positive metastatic NSCLC.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Responses will be compared subject's baseline assessment and historical controls using pembrolizumab monotherapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate toxicities (CTCAE v5.0 scoring) of pembrolizumab and itacitinib in patients with previously untreated, PD-L1 positive metastatic NSCLC</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median progression free survival (PFS) for subjects treated with pembrolizumab and itacitinib.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) for subjects treated with pembrolizumab and itacitinib.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) for subjects treated with pembrolizumab and itacitinib.</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Itacitinib and Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itacitinib</intervention_name>
    <description>a JAK 1 selective small molecule inhibitor</description>
    <arm_group_label>Itacitinib and Pembrolizumab</arm_group_label>
    <other_name>INCB039110</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>a highly selective humanized monoclonal antibody (mAb)</description>
    <arm_group_label>Itacitinib and Pembrolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Stage IV or metastatic non-small cell lung cancer (NSCLC)&#xD;
&#xD;
          -  2. Provide written informed consent for the trial.&#xD;
&#xD;
          -  3. Patients ≥ 18 years of age&#xD;
&#xD;
          -  4. Tumor PD-L1≥ 50% as assessed by the PD-L1 IHC 22C3 pharmDx assay (Dako North&#xD;
             America).&#xD;
&#xD;
          -  5. Subject must have adequate tumor burden at a safely accessible site for biopsy.&#xD;
             NOTE: If sites chosen for biopsy were previously irradiated, there must be evidence of&#xD;
             tumor growth/viable tumor as assessed by the investigator.&#xD;
&#xD;
          -  6. At least one measurable lesion according to Response Evaluation Criteria in Solid&#xD;
             Tumors (RECIST) v1.1&#xD;
&#xD;
          -  7. ECOG performance status 0 or 1&#xD;
&#xD;
          -  8. Adequate Organ Function Laboratory Values: Absolute neutrophil count (ANC)&#xD;
             ≥1,250/mcL; Platelets ≥100,000/mcL; Hemoglobin ≥9 g/dL or ≥5.6 mmol/L; Serum&#xD;
             creatinine ≤1.5 X upper limit of normal (ULN) OR Measured or calculated creatinine&#xD;
             clearance (GFR can also be used in place of creatinine or CrCl) ≥50 mL/min for subject&#xD;
             with creatinine levels &gt; 1.5 X institutional ULN; Serum total bilirubin ≤ 1.5 X ULN OR&#xD;
             Direct bilirubin ≤ ULN for subjects with total bilirubin levels &gt; 1.5 ULN; AST (SGOT)&#xD;
             and ALT (SGPT) ≤ 2.5 X ULN OR ≤ 5 X ULN for subjects with liver metastases&#xD;
&#xD;
          -  9. Subjects of reproductive potential must agree to use acceptable birth control&#xD;
             methods.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Sensitizing mutations in Epidermal growth factor receptor (EGFR) or anaplastic&#xD;
             lymphoma kinase (ALK) or ROS1 proto-oncogene receptor tyrosine kinase (ROS1)&#xD;
             translocations&#xD;
&#xD;
          -  2. Currently participating in or has participated in a study of an investigational&#xD;
             agent or anticipated use of an investigational device within 4 weeks of the first dose&#xD;
             of study treatment.&#xD;
&#xD;
          -  3. Untreated symptomatic central nervous system (CNS) metastases and/or carcinomatous&#xD;
             meningitis.&#xD;
&#xD;
          -  4. Received prior systemic cytotoxic chemotherapy, biologic therapy, targeted therapy&#xD;
             or immunotherapy for incurable (metastatic) NSCLC.&#xD;
&#xD;
          -  5. Diagnosis of immunodeficiencywithin 7 days prior to eligibility confirmation by the&#xD;
             physician-investigator.&#xD;
&#xD;
          -  6. Prior monoclonal antibodies used for the treatment of NSCLC within 4 weeks prior to&#xD;
             eligibility confirmation by the physician-investigator, or individuals who have not&#xD;
             recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents&#xD;
             administered more than 4 weeks earlier.&#xD;
&#xD;
          -  7. Known additional malignancy that is progressing or requires active treatment.&#xD;
             Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the&#xD;
             skin, non-invasive bladder tumors, or in situ cervical cancer&#xD;
&#xD;
          -  8. 8. Active autoimmune disease requiring systemic immunosuppressive treatment within&#xD;
             the past 3 months prior to eligibility confirmation by the physician-investigator.&#xD;
             Subjects that require intermittent use of steroid-containing bronchodilators or local&#xD;
             steroid injections or topical steroid medications are not excluded from the study.&#xD;
             Subjects with hypothyroidism stable on hormone replacement or Sjogren's syndrome are&#xD;
             not excluded from the study.&#xD;
&#xD;
          -  9. Interstitial lung disease or history of pneumonitis that has required oral or IV&#xD;
             steroids&#xD;
&#xD;
          -  10. Active infection requiring systemic therapy with IV antibiotics&#xD;
&#xD;
          -  11. History or current evidence of any condition, therapy, or laboratory abnormality&#xD;
             that might confound the results of the trial, interfere with the subject's&#xD;
             participation for the full duration of the trial, or is not in the best interest of&#xD;
             the subject to participate, in the opinion of the treating investigator.&#xD;
&#xD;
          -  12. Known psychiatric or substance abuse disorders that would interfere with&#xD;
             cooperation with the requirements of the trial.&#xD;
&#xD;
          -  13. Pregnant or breastfeeding women&#xD;
&#xD;
          -  14. Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or&#xD;
             anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4).&#xD;
&#xD;
          -  15. Known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).&#xD;
&#xD;
          -  16. Known active Hepatitis B (e.g., HBsAg positive or HBV DNA detectable) or Hepatitis&#xD;
             C (e.g., HCV RNA [qualitative] is detected).&#xD;
&#xD;
          -  17. Anticipated receipt of any live vaccine within 30 days prior to the first dose of&#xD;
             trial treatment.&#xD;
&#xD;
        Note: For the purposes of determining eligibility above, enrollment is defined as the date&#xD;
        of subject consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corey Langer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 22, 2018</study_first_submitted>
  <study_first_submitted_qc>February 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2018</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

